<DOC>
	<DOCNO>NCT00267709</DOCNO>
	<brief_summary>The purpose study evaluate intravenous ( injection ) investigational medication treat Crohn 's disease patient least one perianal fistula . The research conduct 5 clinical research sit US Europe open men woman age 18 70 year old . Participants study number visit research site 17 month period . All study-related care medication provide qualified participant cost : include visit , examination laboratory work . Visilizumab humanize antibody ( antibody proteins normally make immune system help defend body infection foreign substance ) direct T cell . Visilizumab selectively attack problematic T cell , , may prevent cause inflammation . Visilizumab also observe suppressive effect body 's immune system ( system body react foreign occasionally one 's protein ) .</brief_summary>
	<brief_title>Visilizumab Treatment Perianal Fistulas Crohn 's Disease</brief_title>
	<detailed_description>PDL BioPharma , Inc. formerly know Protein Design Labs , Inc .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Fistula</mesh_term>
	<criteria>1870 year old Diagnosis Crohn 's disease fistula Test negative Clostridium difficile within 3 week Signed informed consent , include permission use protect health information . History lymphoproliferative disorder prior malignancy within 5 year current malignancy Pregnant nursing HIV , Hepatitis B Hepatitis C infection Presence obstructive symptom , confirm endoscopy , within 6 month Likely require surgery next 6 month Serious active infection within 1 year Active infection require antibiotic therapy Serious infection require IV antibiotic hospitalization within 8 week Started change dose sulfasalazine , 5aminosalicylic acid ( 5ASA ) , antibiotic , probiotic , topical therapy Crohn 's within 2 week Had increase dose corticosteroid within 2 week Received live vaccine within 6 week Received monoclonal antibody investigational agent within 3 month Received cyclosporine tacrolimus ( FK506 ) within 4 week Dose change discontinuation 6mercaptopurine , azathioprine , methotrexate within 4 week Significant organ dysfunction History lymphoproliferative disorder History tuberculosis , mycobacterial infection , positive chest xray History thrombophlebitis pulmonary embolus History immune deficiency autoimmune disorder ( Crohn 's disease ) History seizure subtherapeutic level anticonvulsive medication within one week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>